Latest Pharma Insights
UroGen Moves Toward FDA Filing For UGN-103
The company announced positive durability of response results for its next-generation drug in recurrent low-grade intermediate risk non-muscle-invasive bladder cancer.
Scrip - May 15, 2026
The company announced positive durability of response results for its next-generation drug in recurrent low-grade intermediate risk non-muscle-invasive bladder cancer.
Scrip - May 15, 2026
Podcast: Jeremy Levin Offers A Prescription For A Stronger Biotech Industry
Longtime biotech exec Levin talked to Scrip about concerns that the US is falling behind China and discussed how long-term investment in biotech needs to embrace risk.
Scrip - May 15, 2026
Longtime biotech exec Levin talked to Scrip about concerns that the US is falling behind China and discussed how long-term investment in biotech needs to embrace risk.
Scrip - May 15, 2026
Terumo Sets Sights on Top-Tier Medtech Status After Fifth Consecutive Year of Growth
Terumo posted a fifth consecutive year of record sales and previewed higher growth targets under its next strategic plan, GS31, but faces headwinds from tariff uncertainty and neurovascular competition.
Medtech Insight - May 15, 2026
Terumo posted a fifth consecutive year of record sales and previewed higher growth targets under its next strategic plan, GS31, but faces headwinds from tariff uncertainty and neurovascular competition.
Medtech Insight - May 15, 2026
GLP-1 And The Rise Of ‘E-Pommerce’ – Should The OTC Industry Be Worried?
The online commoditization of Rx drugs like GLP-1 weight loss treatments is changing the rules of the game for consumer health. While industry should not ignore this emerging threat, there is plenty of opportunity for sensible, evidence-based innovation tailored to support GLP-1 users.
HBW Insight - May 15, 2026
The online commoditization of Rx drugs like GLP-1 weight loss treatments is changing the rules of the game for consumer health. While industry should not ignore this emerging threat, there is plenty of opportunity for sensible, evidence-based innovation tailored to support GLP-1 users.
HBW Insight - May 15, 2026
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Generics Bulletin - May 15, 2026
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Generics Bulletin - May 15, 2026
ANI Pharma’s Generics Success Continues To Bolster Rare Disease Business
ANI’s first earnings report of 2026 outlines the strategic significance of its generics business to generate meaningful cash flow to support its rare disease interests.
Generics Bulletin - May 15, 2026
ANI’s first earnings report of 2026 outlines the strategic significance of its generics business to generate meaningful cash flow to support its rare disease interests.
Generics Bulletin - May 15, 2026
France’s Innate Backs Cancer Pipeline But Cash Clock Is Ticking
The Marseille-based biotech’s survival hopes are based on getting a partnership pact signed very soon for lacutamab.
Scrip - May 15, 2026
The Marseille-based biotech’s survival hopes are based on getting a partnership pact signed very soon for lacutamab.
Scrip - May 15, 2026
Executives On The Move: Sail Biomedicines Get A New CMO From Merck
Recent moves in the industry include changes at the top at Adalvo, Spruce Biosciences and Artios Pharma, plus Artios Pharma gets a new chief business officer from Eli Lilly.
Scrip - May 15, 2026
Recent moves in the industry include changes at the top at Adalvo, Spruce Biosciences and Artios Pharma, plus Artios Pharma gets a new chief business officer from Eli Lilly.
Scrip - May 15, 2026
MedTech Forum 2026 Podcast: CE-Marking In GB, New MHRA Regs, UK View Of EU MDR Revision
ABHI's Steve Lee says UK industry foresees friction-free future in medtech regulation.
Medtech Insight - May 15, 2026
ABHI's Steve Lee says UK industry foresees friction-free future in medtech regulation.
Medtech Insight - May 15, 2026
Execs On The Move: May 4–8, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 15, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 15, 2026
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause
The FDA’s decision to place ARD-101 on full clinical hold has shifted attention toward Aardvark’s planned unblinding of Phase III data as the company reassesses the future of its lead Prader-Willi syndrome program.
Scrip - May 15, 2026
The FDA’s decision to place ARD-101 on full clinical hold has shifted attention toward Aardvark’s planned unblinding of Phase III data as the company reassesses the future of its lead Prader-Willi syndrome program.
Scrip - May 15, 2026
Regenxbio’s DMD Win Raises As Many Questions As It Answers
Positive gene therapy data couldn't stop a 40% share drop as investors weighed Regenxbio's limited cash runway against a murky regulatory outlook.
Scrip - May 15, 2026
Positive gene therapy data couldn't stop a 40% share drop as investors weighed Regenxbio's limited cash runway against a murky regulatory outlook.
Scrip - May 15, 2026
‘There Is No Single, Global Go?To?Market Model For GLP?1s’ – Biocon’s Tambe Discusses Strategy
With the race for GLP-1 generics heating up in multiple territories, Biocon Ltd CEO and managing director Shreehas Tambe discusses the varying natures of global markets and the need for tailored strategies, while warning that a “race to the bottom” on pricing is not viable or responsible.
Generics Bulletin - May 15, 2026
With the race for GLP-1 generics heating up in multiple territories, Biocon Ltd CEO and managing director Shreehas Tambe discusses the varying natures of global markets and the need for tailored strategies, while warning that a “race to the bottom” on pricing is not viable or responsible.
Generics Bulletin - May 15, 2026
Financing Quarterly Statistics, Q1 2026
During Q1, biopharmas brought in an aggregate $35.9bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $256m.
In Vivo - May 15, 2026
During Q1, biopharmas brought in an aggregate $35.9bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $256m.
In Vivo - May 15, 2026
Dexcom Targets Late 2027 G8 Launch As It Bets On Body-Adaptive CGM Technology
Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.
Medtech Insight - May 15, 2026
Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.
Medtech Insight - May 15, 2026
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Scrip - May 15, 2026
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Scrip - May 15, 2026
MHRA Seeks To Lead World In Digital Mental Health Guidance
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
Medtech Insight - May 15, 2026
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
Medtech Insight - May 15, 2026
Apotex Leapfrogs Dr Reddy’s With First Canadian Semaglutide Launch
Stealing a march on rival Dr Reddy’s, Canadian generics giant Apotex has announced the first launch of a generic version of Ozempic for diabetes in its domestic market.
Generics Bulletin - May 15, 2026
Stealing a march on rival Dr Reddy’s, Canadian generics giant Apotex has announced the first launch of a generic version of Ozempic for diabetes in its domestic market.
Generics Bulletin - May 15, 2026
‘Seize The Global Initiative,’ MedTech Forum 2026 Tells European Leaders
Simplified regulation, more momentum towards technology adoption, better investment flows, resilience – if not quite protectionism – and above all “market access predictability in Europe.” These were the top wish-list sentiments voiced at the MedTech Forum 2026 in Stockholm, Sweden.
Medtech Insight - May 15, 2026
Simplified regulation, more momentum towards technology adoption, better investment flows, resilience – if not quite protectionism – and above all “market access predictability in Europe.” These were the top wish-list sentiments voiced at the MedTech Forum 2026 in Stockholm, Sweden.
Medtech Insight - May 15, 2026
With Selective Targeting, HaemaLogiX Eyes Crowded Multiple Myeloma Space
HaemaLogix is backing its monoclonal antibody targeting Kappa myeloma antigen to carve out space in one of oncology's most crowded markets.
Scrip - May 15, 2026
HaemaLogix is backing its monoclonal antibody targeting Kappa myeloma antigen to carve out space in one of oncology's most crowded markets.
Scrip - May 15, 2026
Podcast: Kurma’s €215m Fund And What It Says About European Funding Environment
Kurma Partners closed BioFund IV at €215m, €35m short of target, as Europe's biotech sector grapples with thin early-stage capital and heavy reliance on non-European investors.
In Vivo - May 15, 2026
Kurma Partners closed BioFund IV at €215m, €35m short of target, as Europe's biotech sector grapples with thin early-stage capital and heavy reliance on non-European investors.
In Vivo - May 15, 2026
GlycoNex Progresses Novel Glycan-Targeted ADC To Clinic
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
US Consumer Health Weekly News Digest: Business, Regulation, Science
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
UroGen Moves Toward FDA Filing For UGN-103
The company announced positive durability of response results for its next-generation drug in recurrent low-grade intermediate risk non-muscle-invasive bladder cancer.
Scrip - May 15, 2026
The company announced positive durability of response results for its next-generation drug in recurrent low-grade intermediate risk non-muscle-invasive bladder cancer.
Scrip - May 15, 2026
Podcast: Jeremy Levin Offers A Prescription For A Stronger Biotech Industry
Longtime biotech exec Levin talked to Scrip about concerns that the US is falling behind China and discussed how long-term investment in biotech needs to embrace risk.
Scrip - May 15, 2026
Longtime biotech exec Levin talked to Scrip about concerns that the US is falling behind China and discussed how long-term investment in biotech needs to embrace risk.
Scrip - May 15, 2026
France’s Innate Backs Cancer Pipeline But Cash Clock Is Ticking
The Marseille-based biotech’s survival hopes are based on getting a partnership pact signed very soon for lacutamab.
Scrip - May 15, 2026
The Marseille-based biotech’s survival hopes are based on getting a partnership pact signed very soon for lacutamab.
Scrip - May 15, 2026
Executives On The Move: Sail Biomedicines Get A New CMO From Merck
Recent moves in the industry include changes at the top at Adalvo, Spruce Biosciences and Artios Pharma, plus Artios Pharma gets a new chief business officer from Eli Lilly.
Scrip - May 15, 2026
Recent moves in the industry include changes at the top at Adalvo, Spruce Biosciences and Artios Pharma, plus Artios Pharma gets a new chief business officer from Eli Lilly.
Scrip - May 15, 2026
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause
The FDA’s decision to place ARD-101 on full clinical hold has shifted attention toward Aardvark’s planned unblinding of Phase III data as the company reassesses the future of its lead Prader-Willi syndrome program.
Scrip - May 15, 2026
The FDA’s decision to place ARD-101 on full clinical hold has shifted attention toward Aardvark’s planned unblinding of Phase III data as the company reassesses the future of its lead Prader-Willi syndrome program.
Scrip - May 15, 2026
Regenxbio’s DMD Win Raises As Many Questions As It Answers
Positive gene therapy data couldn't stop a 40% share drop as investors weighed Regenxbio's limited cash runway against a murky regulatory outlook.
Scrip - May 15, 2026
Positive gene therapy data couldn't stop a 40% share drop as investors weighed Regenxbio's limited cash runway against a murky regulatory outlook.
Scrip - May 15, 2026
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Scrip - May 15, 2026
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Scrip - May 15, 2026
With Selective Targeting, HaemaLogiX Eyes Crowded Multiple Myeloma Space
HaemaLogix is backing its monoclonal antibody targeting Kappa myeloma antigen to carve out space in one of oncology's most crowded markets.
Scrip - May 15, 2026
HaemaLogix is backing its monoclonal antibody targeting Kappa myeloma antigen to carve out space in one of oncology's most crowded markets.
Scrip - May 15, 2026
GlycoNex Progresses Novel Glycan-Targeted ADC To Clinic
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Terumo Sets Sights on Top-Tier Medtech Status After Fifth Consecutive Year of Growth
Terumo posted a fifth consecutive year of record sales and previewed higher growth targets under its next strategic plan, GS31, but faces headwinds from tariff uncertainty and neurovascular competition.
Medtech Insight - May 15, 2026
Terumo posted a fifth consecutive year of record sales and previewed higher growth targets under its next strategic plan, GS31, but faces headwinds from tariff uncertainty and neurovascular competition.
Medtech Insight - May 15, 2026
MedTech Forum 2026 Podcast: CE-Marking In GB, New MHRA Regs, UK View Of EU MDR Revision
ABHI's Steve Lee says UK industry foresees friction-free future in medtech regulation.
Medtech Insight - May 15, 2026
ABHI's Steve Lee says UK industry foresees friction-free future in medtech regulation.
Medtech Insight - May 15, 2026
Execs On The Move: May 4–8, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 15, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 15, 2026
Dexcom Targets Late 2027 G8 Launch As It Bets On Body-Adaptive CGM Technology
Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.
Medtech Insight - May 15, 2026
Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.
Medtech Insight - May 15, 2026
MHRA Seeks To Lead World In Digital Mental Health Guidance
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
Medtech Insight - May 15, 2026
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
Medtech Insight - May 15, 2026
‘Seize The Global Initiative,’ MedTech Forum 2026 Tells European Leaders
Simplified regulation, more momentum towards technology adoption, better investment flows, resilience – if not quite protectionism – and above all “market access predictability in Europe.” These were the top wish-list sentiments voiced at the MedTech Forum 2026 in Stockholm, Sweden.
Medtech Insight - May 15, 2026
Simplified regulation, more momentum towards technology adoption, better investment flows, resilience – if not quite protectionism – and above all “market access predictability in Europe.” These were the top wish-list sentiments voiced at the MedTech Forum 2026 in Stockholm, Sweden.
Medtech Insight - May 15, 2026
GLP-1 And The Rise Of ‘E-Pommerce’ – Should The OTC Industry Be Worried?
The online commoditization of Rx drugs like GLP-1 weight loss treatments is changing the rules of the game for consumer health. While industry should not ignore this emerging threat, there is plenty of opportunity for sensible, evidence-based innovation tailored to support GLP-1 users.
HBW Insight - May 15, 2026
The online commoditization of Rx drugs like GLP-1 weight loss treatments is changing the rules of the game for consumer health. While industry should not ignore this emerging threat, there is plenty of opportunity for sensible, evidence-based innovation tailored to support GLP-1 users.
HBW Insight - May 15, 2026
US Consumer Health Weekly News Digest: Business, Regulation, Science
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Generics Bulletin - May 15, 2026
Zydus' acquisition of US firm Assertio gives it an oncology asset developed by Hanmi Pharma and a growth platform. Rolvedon's US revenues might peak in 2029 as per Evaluate Pharma's data but the drug could have potential elsewhere.
Generics Bulletin - May 15, 2026
ANI Pharma’s Generics Success Continues To Bolster Rare Disease Business
ANI’s first earnings report of 2026 outlines the strategic significance of its generics business to generate meaningful cash flow to support its rare disease interests.
Generics Bulletin - May 15, 2026
ANI’s first earnings report of 2026 outlines the strategic significance of its generics business to generate meaningful cash flow to support its rare disease interests.
Generics Bulletin - May 15, 2026
‘There Is No Single, Global Go?To?Market Model For GLP?1s’ – Biocon’s Tambe Discusses Strategy
With the race for GLP-1 generics heating up in multiple territories, Biocon Ltd CEO and managing director Shreehas Tambe discusses the varying natures of global markets and the need for tailored strategies, while warning that a “race to the bottom” on pricing is not viable or responsible.
Generics Bulletin - May 15, 2026
With the race for GLP-1 generics heating up in multiple territories, Biocon Ltd CEO and managing director Shreehas Tambe discusses the varying natures of global markets and the need for tailored strategies, while warning that a “race to the bottom” on pricing is not viable or responsible.
Generics Bulletin - May 15, 2026
Apotex Leapfrogs Dr Reddy’s With First Canadian Semaglutide Launch
Stealing a march on rival Dr Reddy’s, Canadian generics giant Apotex has announced the first launch of a generic version of Ozempic for diabetes in its domestic market.
Generics Bulletin - May 15, 2026
Stealing a march on rival Dr Reddy’s, Canadian generics giant Apotex has announced the first launch of a generic version of Ozempic for diabetes in its domestic market.
Generics Bulletin - May 15, 2026
Financing Quarterly Statistics, Q1 2026
During Q1, biopharmas brought in an aggregate $35.9bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $256m.
In Vivo - May 15, 2026
During Q1, biopharmas brought in an aggregate $35.9bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $256m.
In Vivo - May 15, 2026
Podcast: Kurma’s €215m Fund And What It Says About European Funding Environment
Kurma Partners closed BioFund IV at €215m, €35m short of target, as Europe's biotech sector grapples with thin early-stage capital and heavy reliance on non-European investors.
In Vivo - May 15, 2026
Kurma Partners closed BioFund IV at €215m, €35m short of target, as Europe's biotech sector grapples with thin early-stage capital and heavy reliance on non-European investors.
In Vivo - May 15, 2026